Lilly, a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world has announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and…